Brief: Masonic Cancer Center At University Of Minnesota Receives FDA Clearance To Proceed With Phase 1 Clinical Trial In Solid Tumors For HCW9218
24/01/2022 12:55
Jan 24 (Reuters) - HCW Biologics Inc HCWB.O :
* MASONIC CANCER CENTER AT UNIVERSITY OF MINNESOTA RECEIVES
FDA
CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL IN SOLID TUMORS
FOR HCW9218, HCW BIOLOGICS' NOVEL BIFUNCTIONAL FUSION PROTEIN
Source text for Eikon: ID:nGNX5z5w2P
Further company coverage: HCWB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: Hcw Biologics Maintains Momentum Toward Completion Of Ind Application For Clinical Study To Evaluate Lead T-Cell Engager In Solid Tumors
Brief: HCW Biologics Registers Resale Of Up To 1.81 Mln Shares Of Common Stock By Selling Stockholder- SEC Filing
NASDAQ RESUMED AT 10:34 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:29 AM
NASDAQ RESUMED AT 10:29 AM